Introduction: Urologists face challenges in obtaining public research funding, leading to increasing reliance on the industry for research support. This study aimed to examine the extent and trends in industry-sponsored research payments to urologists from 2014 to 2022 in the United States.

Methods: We identified all US urologists using the Centers for Medicare and Medicaid Services National Plan and Provider Enumeration System database and extracted their industry-sponsored research payments data from the Centers for Medicare and Medicaid Services Open Payments Database. We performed descriptive analyses of the payments data.

Results: Among 13,902 US urologists, 1330 (9.6%) received at least one industry-sponsored research payment. Urologists received $605.1 million between 2014 and 2022. Of all research payments, 98.7% ($597.4 million) were associated research payments for research where urologists served as principal investigators. The top 10% of urologists in research payments received 79.3% ($480.0 million) of total research payments. Only 0.4% ($2.3 million) of research payments were for preclinical research, whereas registered clinical trials totaled $159.0 million (26.3% of all research payments). The annual value of research payments increased from $35.2 million in 2014 to $101.7 million in 2022. The average percentage change in total payments showed a significant annual increase of 13.9% (95% CI, 11.6%-16.3%; < .001) in value. There was no significant trend in the number of urologists receiving research payments.

Conclusions: Industry-sponsored research payments to urologists are substantial and have increased in both payment amount and number over time.

Download full-text PDF

Source
http://dx.doi.org/10.1097/UPJ.0000000000000742DOI Listing

Publication Analysis

Top Keywords

payments
13
2014 2022
12
industry-sponsored payments
12
payments urologists
12
urologists
10
centers medicare
8
medicare medicaid
8
medicaid services
8
total payments
8
payments annual
8

Similar Publications

Limited data are available on VWF activity (VWF:Act) and factor VIII (FVIII:C) levels during delivery after VWF/FVIII concentrate administration in women with von Willebrand disease (VWD). We aimed to evaluate treatment with a specific VWF/FVIII concentrate on factor levels in women with VWD during delivery and the postpartum period. A retrospective single-center study was conducted between January 1, 2008, and August 1, 2022.

View Article and Find Full Text PDF

Objective: This study aims to compare the effectiveness of 2 artificial saliva substitutes (Biotène vs HydraSmile) in the symptomatic management of radiation-induced xerostomia.

Study Design: Randomized double-blind cross-over study.

Setting: Single tertiary care academic institution.

View Article and Find Full Text PDF

Background: Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment of epidermal growth factor receptor ()-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated.

Objective: To study the cost-effectiveness of lazertinib as a first-line treatment for patients with -mutated advanced lung cancer.

View Article and Find Full Text PDF

Consensus on the lung cancer management after third-generation EGFR-TKI resistance.

Lancet Reg Health West Pac

December 2024

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

Lung cancer is the most prevalent malignant tumour in the Asia-Pacific region. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers. Among these, the rate of mutations in Asian patients with lung adenocarcinoma is 40-60%.

View Article and Find Full Text PDF

Erythrodermic psoriasis (EP) is a rare and challenging-to-diagnose severe form of psoriasis. Its presentation can have similarities with other inflammatory skin conditions, complicating subsequent management. We present a case of a 76-year-old woman with EP who presented with fever, tachycardia, leg swelling with pain and redness, and reduced consciousness.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!